Exact Sciences Licenses OncoMethylome Biomarkers | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Exact Sciences has licensed exclusive, worldwide rights from OncoMethylome Sciences to DNA methylation biomarkers for use in the stool-based detection of colorectal cancer.

In addition, Madison, Wis.-based Exact Sciences also licensed non-exclusive access to part of OncoMethylome's platform technology. In return, the Belgian firm will receive milestone payments and royalties on net sales

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: new single-cell RNA sequencing technique to study proliferating cells, and more.

South African researchers uncover bone cancer in an ancient hominin ancestor.

English bulldogs suffer from low genetic diversity and might have to be outbred to improve their health, according to a new study.

Theresa May tries to reassure researchers about the UK's commitment to science, New Scientist reports.